Blueprint Medicines

Company snapshot

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and d

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Blueprint Medicines. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Blueprint Medicines.

1. Jun 8, 2026 Clinical update

   BLU-285-3101 — Phase 2

2. Jun 8, 2026 Clinical update

   BLU-808-1201 — Phase 2

3. Jun 8, 2026 Clinical update

   BLU-285-2203 — Phase 2

4. Jun 8, 2026 Clinical update

   BLU-263-1201 — Phase 3

5. Jun 8, 2026 Clinical update

   avapritinib — Phase 3

View all clinical trial activity →

• What is Blueprint Medicines?

  Blueprint Medicines (Netherlands) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Advanced Systemic Mastocytosis, Systemic Mastocytosis, GIST, Indolent Systemic Mastocytosis, Indolent Systemic Mastocytosis and SSM. NovaPharmaNews links 8 clin

• Is Blueprint Medicines publicly traded?

  Blueprint Medicines appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Blueprint Medicines develop or market?

  We link 9 drug profile(s) where Blueprint Medicines is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/blueprint-medicines-netherlands-b-v#company-drugs.

• What are the latest developments for Blueprint Medicines?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Blueprint Medicines focus on?

  Blueprint Medicines focuses on Advanced Systemic Mastocytosis, Systemic Mastocytosis, GIST based on our analysis of their pipeline programs and drug development activities.